There are currently 200 ongoing clinical trials involving Tuberculosis
Of the 200 trials,66 trials are in Phase II
Furthermore, 36 trials are in Phase III
The global pharmaceutical industry is steadily developing new drugs for Tuberculosis, an Infectious Disease condition. The largest number of ongoing clinical trials for Tuberculosis is conducted in the Asia-Pacific region. Europe and Middle East and Africa are among some of the other prominent regions engaged in Tuberculosis-related drug trials.
The National Institute of Allergy and Infectious Diseases: The leading ongoing Tuberculosis related clinical trial sponsor
The National Institute of Allergy and Infectious Diseases is the top sponsor for Tuberculosis-related ongoing clinical trials.
Beijing Chest Hospital , Global Alliance for TB Drug Development, Medecins Sans Frontieres and Huashan Hospital are among other notable clinical trial sponsors involved in Tuberculosis. A clinical trial sponsor can be a Company, Government, Individual, or Institution.
Marketed Drugs involving Tuberculosis
Albuterol sulfate, Methylprednisolone and Levofloxacin are among the key marketed drugs involving Tuberculosis.
Albuterol sulfate is a short acting broncholidator agent. It functions via Beta 2 Adrenergic Receptor (Beta 2 Adrenoreceptor or ADRB2) Agonist mechanism of action. Albuterol sulfate is formulated as metered aerosol, powder, capsules, solution, suspension for inhalation route, as tablets, syrup for oral route, and as injectable solution for intravenous, intramuscular and subcutaneous, intravenous bolus route of administration. Albuterol sulfate was first approved in 1971 and is marketed globally in the US, UK, China, Japan, Germany, and France by several prominent pharma giants including GlaxoSmithKline LLC.
Methylprednisolone is a glucocorticoid, anti-inflammatory agent. It functions via Glucocorticoid Receptor (GR or Nuclear Receptor Subfamily 3 Group C Member 1 or NR3C1) Agonist mechanism of action. Methylprednisolone is formulated as tablets for oral administration, lyophilized powder for solution, suspension and solution for intravenous, intramuscular, intraarticular, intralesional, intrasynovial route of administration. Methylprednisolone was first approved in 1957 and is marketed globally in the US, UK, France, Germany, China and Japan by several prominent pharma giants including Pfizer Inc.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward